Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05201287
Other study ID # VIA-2021-001
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date December 30, 2021
Est. completion date July 31, 2024

Study information

Verified date April 2023
Source VIVEX Biologics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

VIA Disc NP is an allograph intended to supplement the nucleus pulposus tissue in degenerated intervertebral discs.


Description:

The study will include adult subjects, ages 18 years or older, with symptomatic lumbar intervertebral disc degeneration that is not adequately resolved by non-surgical standard care. For the purpose of the primary analysis, subjects are considered enrolled in the study once they have signed the informed consent. Each subject will receive one injection per level and be evaluated for efficacy and safety during the 24 month observation period. The study is expected to be completed within 26 months, inclusive of enrollment and follow-up for all subjects. Subjects will be evaluated at baseline and followed through 24 months to establish safety and efficacy of the treatment. The expected duration of subject participation from screening/enrollment through final follow-up is 104 weeks.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 35
Est. completion date July 31, 2024
Est. primary completion date March 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Eligibility for inclusion is evaluated on a site-specific basis based on each subject's medical, clinical, and radiographic presentation. In addition, for study consistency purposes, the MRI imaging will be submitted to Medical Metrics Imaging (MMI), a core lab, for independent review. MMI will review imaging of every subject to confirm radiographic inclusion criteria. The Medical Monitor will make the final determination for inclusion on all subjects based on review of the MRI relevant medical history and source documents. 1. Age 18 years or older; 2. Body mass index (BMI) < 35; 3. Documented diagnosis of moderate radiographic degeneration of up to 2 intervertebral discs from L1 to S1, with a suspected associated discogenic chronic low back pain; 4. Chronic LBP for = 6 months; 5. Failed conservative care over the past 3 months of at least 2 conservative treatments including: 1. oral pain medication [analgesics, steroids and/or non-steroidal anti-inflammatory drugs (NSAIDs)], 2. structured physical therapy or exercise program prescribed by physical therapist, chiropractor provider or physician specifically for the treatment of low back pain, and 3. epidural steroid injections and/or facet injections/selective nerve blocks; 6. An MRI demonstrating: 1. 1 to 2 vertebral level involvement L1-S1; 2. Modified Pfirrmann Grade 3-7; 3. No modic changes or if changes = 2; 7. Oswestry Disability Index (ODI) score at time of evaluation of = 40 and = 80 points; 8. Low back pain of Baseline Numeric Rating Scale (NRS) score of = 6 on the 11-point scale; 9. No signs or symptoms of current infection; 10. Be able to give voluntary, written informed consent to participate and have signed an Informed Consent Form specific to this study; 11. Be willing and able to comply with all study procedures and availability for the duration of the study with a life expectancy of > 2 years. Exclusion Criteria: 1. Known allergies to components of VIA Disc NP, Gentamicin, or Vancomycin; 2. Contraindications to the proposed sedation/anesthetic protocol; 3. Radicular pain greater than back pain by history or evidence of radicular pain or neurological deficit within the past 6 months. Radicular pain is defined as nerve pain following a dermatomal distribution and that correlates with nerve compression on imaging. Somatic referred pain is allowed; 4. Any of the following conditions at the index level: 1. Contained disc protrusion >5 mm or disc extrusion, or spondylolisthesis >5 mm (lysis and degenerative); 2. Seronegative spondyloarthropathy; 3. Symptomatic spinal stenosis (moderate to severe in degree); 4. Chronic facet syndrome; 5. Spondylodiscitis; 6. Bilateral spondylolysis; 7. Current or history of osteoporotic or tumor-related vertebral body compression fracture; 8. Previous lumbar spine fusion surgery or disc arthroplasty; 5. History of sacroiliac (SI) joint pain/injections during the past 3 months or SI joint fusion within the past two years; 6. Received chemonucleolysis or percutaneous treatment of the affected disc prior to the study; 7. History of epidural steroid injections within 1 week prior to study treatment; 8. Received any lumbar intradiscal treatment injection or procedure (e.g., methylene blue, dextrose, glucosamine, and chondroitin sulfate, or biacuplasty) and any nerve ablation procedures at the same or adjacent level (e.g., Basivertebral nerve ablation, dorsal ramus or sinovertebral nerve ablations). Discography and anaesthetic discography may be performed but must be done at least 2 weeks or more prior to the injection procedure; 9. Been a recipient of prior stem cell/progenitor cell therapy or other biological intervention (e.g., PRP) to repair the target intervertebral disc; 10. Severe motor deficit or cauda equina disorder based on investigator determination; 11. Diagnosis of any traumatic neurological disorders; 12. Severe diseases of any other major body system as judged by the investigator, including malignant diseases of any solid organ or any hematologic malignancy during the previous 5 years; 13. Demonstrate 3 or more Waddell's signs of Inorganic Behavior; 14. Any mental instability, bipolar disorders, post-traumatic stress disorder (PTSD) or uncontrolled anxiety/depression and/or require new or changed anti-depressants or anti-psychotic medications within 3 months of enrollment; 15. Compensated injuries or ongoing litigation regarding back pain/injury, or financial or other incentives to remain impaired; 16. If female and of child-bearing potential, are pregnant or breastfeeding or a plan to become pregnant or breastfeed in the first 12 months post-treatment; 17. Any medical condition that impairs follow-up (i.e., fibromyalgia, rheumatoid arthritis, chronic regional pain syndrome, reflex sympathetic dystrophy); 18. Evidence of substance abuse (including marijuana); Note: subjects using prescribed extended-release narcotics (e.g., fentanyl patch, MS Contin, oxycontin) within the 3 months prior to screening; subjects on long-acting opioids may be given option to wean off opiates before enrollment. Subjects on short-acting opiates (e.g., hydrocodone, oxycodone, tramadol, etc.) may be included and utilization monitored after the treatment; 19. Are currently receiving treatment with radiation, chemotherapy, immunosuppression, or chronic steroid therapy (prednisone, or its equivalent, use of up to 5 mg/qd is allowed, as well as inhalation steroids for asthma); 20. Active implantable devices, such as cardiac pacemakers, spinal cord stimulators, intrathecal pumps, etc.; 21. Bilateral spondylolysis at any level; 22. Fracture of the spine, previous lumbar spine surgery or previous treatment of the target disc.

Study Design


Intervention

Other:
VIA Disc NP
VIA Disc NP is processed from donated cadaveric disc tissue, lyophilized, and micronized to particles.

Locations

Country Name City State
United States Cleveland Clinic Cleveland Ohio
United States Clinical Investigations, LLC Edmond Oklahoma
United States California Orthopedics and Spine Larkspur California
United States Virginia iSpine Richmond Virginia
United States Source Health Santa Monica California
United States IPM Medical Group Walnut Creek California

Sponsors (2)

Lead Sponsor Collaborator
VIVEX Biologics, Inc. MCRA

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient self-reporting of Functional Efficacy with no change in neurological status using the Oswestry Disability Index (ODI) Evaluate the change from baseline in functional disability on the Oswestry Disability Index (ODI) measured from 0 (minimal disability) to 100 (maximal disability). The ODI is 10 categories of function to quantify disability due to low back pain. baseline to 3 months
Primary Review of all Adverse Events for Safety of treatment and product Evaluate the incidence of related Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Events from baseline through the final follow-up visit that are related to treatment and product baseline to 6 months
Secondary Patient self-reporting of Function Owestry Disability Index (ODI) is measured 0 (minimal disability) to 100 (maximal disability). This index is comprised of ten categories of function to quantify disability due to low back pain. Functional responder analysis at 3 and 6 months measured as subjects meeting functional improvement of = 10, 15 and 20 points in ODI scores. 3-6 months
Secondary Patient self-reporting of Pain Changes in Numeric Rating Scale (NRS) scores. Eleven point pain scale used for patient self-reporting of back pain, which ranges from 0 (no pain) to 10 (the worst pain imaginable). Analysis at 3 and 6 months measured as subjects meeting lower back pain NRS improvement of 50%. 3-6 months
Secondary Patient self-reporting of Pain in low back Changes in Numeric Rating Scale (NRS) scores. Eleven-point pain scale used for patient to self-report level of back pain, which ranges from 0 (no pain) to 10 (the worst pain imaginable). Analysis at 3 and 6 months measured as subjects meeting lower back pain NRS improvement of =30%. 3-6 months
Secondary Oswestry Disability Index (ODI) score change Change from baseline in ODI scores at 6 months. Ten category index comprising of function to quantify due to low back pain. ODI is measured 0 (minimal disability) to 100 (maximal disability). baseline and 6 months
Secondary Numeric Rating Scale change Changes from baseline in Numeric Rating Scale (NRS) score at 3 and 6 months. Eleven-point pain scale used for patient self-reporting of pain, which ranges from 0 (no pain) to 10 (the worst pain imaginable). baseline, 3 and 6 months
Secondary Neurological status change Change from baseline in motor function (graded 0 - no movement to 4 - active movement against resistance), reflexes (0 - absence to 4 - abnormal/hyperactive) and sensory status (graded normal or abnormal) based on physician's physical exam at 1, 3, and 6 months. baseline to 6 months
Secondary Return to work Patient reported return to work - same or different capacity responses to employment questions will be assessed across time points and compared. baseline - 6 months
Secondary Magnetic Resonance Imaging (MRI) review to determine disc health changes Magnetic Resonance Imaging (MRI) taken at baseline compared to 6 months reviewing changes in treated disc levels (disc height, volume hydration of disc and Modified Pfirrman grade) baseline-6 months
See also
  Status Clinical Trial Phase
Completed NCT03916705 - Thoraco-Lumbar Fascia Mobility N/A
Completed NCT04007302 - Modification of the Activity of the Prefrontal Cortex by Virtual Distraction in the Lumbago N/A
Completed NCT03273114 - Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain N/A
Recruiting NCT03600207 - The Effect of Diaphragm Muscle Training on Chronic Low Back Pain N/A
Completed NCT04284982 - Periodized Resistance Training for Persistent Non-specific Low Back Pain N/A
Recruiting NCT05600543 - Evaluation of the Effect of Lumbar Belt on Spinal Mobility in Subjects With and Without Low Back Pain N/A
Withdrawn NCT05410366 - Safe Harbors in Emergency Medicine, Specific Aim 3
Completed NCT03673436 - Effect of Lumbar Spinal Fusion Predicted by Physiotherapists
Completed NCT02546466 - Effects of Functional Taping on Static Postural Control in Patients With Non-specific Chronic Low Back Pain N/A
Completed NCT00983385 - Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics Phase 3
Recruiting NCT05156242 - Corticospinal and Motor Behavior Responses After Physical Therapy Intervention in Patients With Chronic Low Back Pain. N/A
Recruiting NCT04673773 - MY RELIEF- Evidence Based Information to Support People Aged 55+ Years Living and Working With Persistent Low-back Pain. N/A
Completed NCT06049251 - ELDOA Technique Versus Lumbar SNAGS With Motor Control Exercises N/A
Completed NCT06049277 - Mulligan Technique Versus McKenzie Extension Exercise Chronic Unilateral Radicular Low Back Pain N/A
Completed NCT04980469 - A Study to Explore the Effect of Vitex Negundo and Zingiber Officinale on Non-specific Chronic Low Back Pain Due to Sedentary Lifestyle N/A
Completed NCT04055545 - High Intensity Interval Training VS Moderate Intensity Continuous Training in Chronic Low Back Pain Subjects N/A
Recruiting NCT05944354 - Wearable Spine Health System for Military Readiness
Recruiting NCT05552248 - Assessment of the Safety and Performance of a Lumbar Belt
Completed NCT05801588 - Participating in T'ai Chi to Reduce Back Pain and Improve Quality of Life N/A
Recruiting NCT05811143 - Examining the Effects of Dorsal Column Stimulation on Pain From Lumbar Spinal Stenosis Related to Epidural Lipomatosis.